Studies how early-stage high-risk bladder cancer is diagnosed and treated in Portugal
Looks at how adults with early high-risk bladder cancer are cared for in Portugal.
Plain-language title generated from the registry record
Registry title: A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
Key facts
- Where
- Lisbon, PortugalSee the site
Where in Portugal
- IPO LisboaLisbon, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen-Cilag Farmaceutica Ltda.
- Trial code
- NCT07784387
- Record updated
- 28 August 2026
- Original description
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.Read full original descriptionShow less
High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) Retrospective Cohort Study
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Inclusion: Bladder cancer diagnosis between January 1, 2016 and December 31, 2020; Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue); Minimal follow-up time of 5 years unless there is premature death event.
Exclusion: History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC; Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1; Participation in any interventional clinical trial during the observation period.